Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin D3 may lower long COVID risk, new study suggests

NCT ID NCT06452082

Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 200 adults from an endocrinology clinic to see if taking vitamin D3 supplements lowered their chances of developing Long COVID after a COVID-19 infection or getting COVID-19 after vaccination. Researchers compared patients who took vitamin D3 with those who did not. The goal was to understand if this common supplement could offer protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Mar 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

outpatients affected by endocrine-metabolic disease with first visit to the Endocrinology Unit carried out between 01/01/2020 and 12/31/2022

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (For aim I): * age ≥18 * outpatient with first visit on Endocrinology Department performed from 01/01/2020 to 31/12/2022 * previous SARS CoV-2 infection * clinical,anamnestic and therapeutic data 6 months post SARS CoV-2 infection * data on cholecalciferol supplementation * signature of informed consent Exclusion Criteria (For aim I): * age ≤ 18 * pregnant or breastfeeding women * patients suffering from primary and/or acquired immunodeficiency and/or severe impairment of general clinical conditions * patients treated with drugs that interfere with vitamin D metabolism * first vaccination anti Sars COVID performed before the acute infection * first vaccination performed within 6 months of the acute infection * patients unable to sign the informed consent Inclusion Criteria (For aim 2) \-- age ≥18 * outpatient with first visit on Endocrinology Department performed from 01/01/2020 to 31/12/2022 * vaccination with BNT162b2 Biontec mRNA Pfizer/BioNtech * clinical, anamnestic and therapeutic data 6 months post SARS CoV-2 infection * data on cholecalciferol supplementation * signature of informed consent Exclusion Criteria (For aim 2): * age ≤ 18 * pregnant or breastfeeding women * patients suffering from primary and/or acquired immunodeficiency and/or severe impairment of general clinical conditions * patients treated with drugs that interfere with vitamin D metabolism * additional vaccination performed before 6-12 months * acute infection before the vaccination * patients unable to sign the informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 vitamin D deficiency long COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19 Long COVID Vitamin D deficiency

Contacts and locations

Locations

  • Luigi di Filippo

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.